Advances in drug development technologies are yielding innovative new therapies, from potentially lifesaving medicines to lifestyle products. In recent years, however, the cost of developing new drugs has soared, and concerns over drug resistance and pharmacoeconomics have come to the fore. Adverse reactions experienced at the clinical trial level serve as a constant reminder of the importance of rigorous safety and toxicity testing. Furthermore the advent of pharmacogenomics and ‘individualized’ approaches to therapy will demand a fresh approach to drug evaluation and healthcare delivery.Clinical Pharmacology provides an essential role in integrating the expertise of all of the specialists and players who are active in meeting such challenges in modern biomedical practice.Expert Review of Clinical Pharmacology (ISSN 1751-2433) provides a forum for informed debate and critical analysis of all aspects of safety, tolerability, efficacy and therapeutic applications, in addition to covering toxicity issues, adverse reactions, pharmacoeconomics and societal issues.Coverage includes:? ADME studies and PK/PD modeling ? Novel clinical trial design and conduct ? Toxicity and carcinogenesis ? Adverse effects/reactions, drug–drug and drug–disease interactions ? Pharmacogenetics, genomics and the incorporation of new biomarkers in drug development and clinical practice ? Translational medicine ? Pharmacoepidemiology, risk management and pharmacovigilance ? Pharmacotherapy in specific patient groups, such as children, women, the immunocompromised ? Pharmacology and ethnicity ? Impact on quality of life and pharmacoeconomic issues ? Regulation of drug development and marketing ? Epidemiology and biostatisticsExpert Review of Clinical Pharmacology bridges the gap between the medical profession, clinical research and the pharmaceutical industry, providing clinical and pharmaceutical researchers, drug development specialists, physicians and other healthcare professionals with the key information they need to assist in the progress of pharmacological therapy.All reviews are subject to rigorous peer review in association with our independent panel of Editorial Board members, representing the key experts in their pharmacological specialties.

藥物開發(fā)技術(shù)的進(jìn)步正在產(chǎn)生創(chuàng)新的新療法，從潛在的救生藥物到生活方式產(chǎn)品。然而，近年來，開發(fā)新藥的成本猛增，人們對(duì)耐藥性和藥物經(jīng)濟(jì)學(xué)的擔(dān)憂也日益突出。在臨床試驗(yàn)階段出現(xiàn)的不良反應(yīng)不斷提醒人們嚴(yán)格的安全性和毒性測(cè)試的重要性。此外，藥物基因組學(xué)和“個(gè)性化”治療方法的出現(xiàn)，將需要一種新的藥物評(píng)估和醫(yī)療保健提供方法。臨床藥理學(xué)在整合所有在現(xiàn)代生物醫(yī)學(xué)實(shí)踐中積極應(yīng)對(duì)此類挑戰(zhàn)的專家和參與者的專業(yè)知識(shí)方面發(fā)揮著重要作用。臨床藥理學(xué)專家評(píng)審（ISSN1751-2433）為安全性、耐受性、療效和治療應(yīng)用的所有方面的知情辯論和關(guān)鍵分析提供了一個(gè)論壇，并涵蓋毒性問題、不良反應(yīng)、藥理學(xué)和社會(huì)問題。覆蓋范圍包括：?ADME研究和PK/PD建模?新穎的臨床試驗(yàn)設(shè)計(jì)和實(shí)施?毒性和致癌作用?不良反應(yīng)/反應(yīng)、藥物-藥物和藥物-疾病相互作用?藥物遺傳學(xué)、基因組學(xué)以及在藥物開發(fā)和臨床實(shí)踐中加入新的生物標(biāo)志物?轉(zhuǎn)化醫(yī)學(xué)?藥物流行病學(xué)、風(fēng)險(xiǎn)管理和藥物警戒?針對(duì)特定患者群體的藥物治療，如兒童、婦女，免疫功能受損?藥理學(xué)和種族?對(duì)生活質(zhì)量和藥物經(jīng)濟(jì)問題的影響?藥品開發(fā)和營銷法規(guī)?流行病學(xué)和生物統(tǒng)計(jì)學(xué)臨床藥理學(xué)專家評(píng)審彌合了醫(yī)療專業(yè)、臨床研究和制藥行業(yè)之間的差距，為臨床和藥物研究人員、藥物開發(fā)專家、醫(yī)生和其他保健專業(yè)人員提供了他們需要的關(guān)鍵信息，以協(xié)助藥物治療的進(jìn)展。所有的評(píng)論都需要與我們獨(dú)立的編輯委員會(huì)成員進(jìn)行嚴(yán)格的同行評(píng)審，代表他們藥理學(xué)專業(yè)的關(guān)鍵專家。